AbCellera Biologics Inc. (ABCL) shares reached a 52-week high of $12.15 on Tuesday, extending a rally that has pushed the stock up 172.54% over the past year and 210.23% year-to-date.
The advance follows positive top-line results from the Phase 2 clinical trial of ABCL635, an investigational treatment for vasomotor symptoms. Truist Securities upgraded its price target on the stock to $30 from $12 and maintained a buy rating, citing the trial outcomes and an estimated $1.1 billion in adjusted risk-adjusted peak sales for the program.
AbCellera reported a narrower adjusted loss of $0.18 per share in the second quarter of 2026, compared with analyst expectations of a $0.17 loss, and revenue of $4.1 million against a projected $8.1 million. The company also completed a $200 million primary public offering of common stock, with proceeds going directly to AbCellera.
Despite missing revenue and earnings expectations, AbCellera emphasized its strengthened cash position and new partnership agreements as key developments. InvestingPro data indicated the stock is trading in overbought territory based on its Relative Strength Index and is considered overvalued relative to its fair value estimate. Analysts do not project profitability for the company in the current year.
The 52-week high of $12.15 marks a significant milestone for AbCellera, which has seen its valuation expand alongside clinical progress and analyst upgrades.
